IP Library Granted Patent US 7,153,505
Granted Patent B2
US 7,153,505 · App. 10/603,501 · Granted Dec 26, 2006

Methods for enlarging the diameter of an artery or vein in a human subject

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,153,505
App. No.
10/603,501
Granted
Dec 26, 2006
Kind
B2
Abstract

The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes preventively dilating a section of conduit to minimize the risk of obstruction formation.

Claims (19)

1. A method for therapeutically increasing the diameter of an artery or vein in a human subject in need thereof, the method comprising:

locally administering to the wall of the artery or vein in the human subject a composition comprising an elastase in a dose sufficient to increase the diameter of the artery or vein.

2. The method of claim 1 , wherein the composition comprises a pancreatic elastase.

3. The method of claim 1 or 2 , wherein the method further comprises inserting a portion of a delivery apparatus into the wall of the artery or vein to deliver elastase to the wall of the artery or vein.

4. The method of claim 1 or 2 , wherein the composition is administered by a catheter.

5. The method of claim 1 or 2 , wherein the composition is administered directly into the wall of the artery or vein.

6. The method of claim 1 or 2 , wherein the artery or vein is obstructed.

7. The method of claim 6 , wherein the artery or vein is obstructed by stenosis.

8. The method of claim 6 , wherein the obstruction permits passage of an insufficient volume of blood prior to the treatment.

9. The method of claim 8 , wherein the obstruction is a stenosis.

10. The method of claim 6 , wherein the artery or vein is obstructed by intirnal hyperplasia.

11. The method of claim 1 or 2 , wherein the composition is administered to an obstructed coronary artery.

12. The method of claim 1 or 2 , wherein the artery or vein is susceptible to obstruction by intimal hyperplasia.

13. The method of claim 12 , wherein the composition is administered to the wall of a vein.

14. The method of claim 13 , wherein the vein is connected to an arteriovenous hemodialysis graft.

15. The method of claim 12 , wherein the vein is for use in hemodialysis.

16. The method of claim 15 , further comprising connecting the vein to an artery via a graft.

17. The method of claim 1 or 2 , wherein the composition does not comprise a collagenase.

18. The method of claim 1 or 2 , wherein the composition is administered to the exterior of the artery or vein.

Assignments (2)
CHANGE OF NAME Recorded Nov 30, 2020
From: ARTARA THERAPEUTICS, INC.
To: PROTARA THERAPEUTICS, INC.
Reel/Frame 054553/0688 →
MERGER Recorded Nov 18, 2020
From: PROTEON THERAPEUTICS, INC.
To: ARTARA THERAPEUTICS, INC.
Reel/Frame 054476/0140 →